findmyKOL

David Gandara, MD

Enriched profile

Professor Emeritus of Medicine; Director, Thoracic Oncology Program; Senior Advisor to the Director, UC Davis Comprehensive Cancer Center · UC Davis Comprehensive Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Sacramento, CA · West · United StatesSpecialtyHematology / OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1997–2025

David Gandara is Professor Emeritus of Medicine; Director, Thoracic Oncology Program; Senior Advisor to the Director, UC Davis Comprehensive Cancer Center at UC Davis Comprehensive Cancer Center. OpenAlex indexes 1,114 publications with 55,117 citations (h-index 100); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 14 Oct 2026

David R. Gandara, M.D., is Professor Emeritus of Medicine at UC Davis Comprehensive Cancer Center, Division of Hematology and Oncology (NOT "Comprehensive Blood & Cancer Center" of Bakersfield, CA, independently re-checked: CBCC's own clinical-team roster (cbccusa.com/clinical-team) lists Ravi Patel, Neal Ammar, Sherif Ammar, Geover Fernandez, David Hsiang, and Kalyan Gaddam, with no Gandara at all. That seed institution is confirmed unrelated to this individual.). The public record shows 1,114 publications with 55,117 citations (h-index 100), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 37 companies, 7 NIH-funded awards (1997–2025).

  • Most recent indexed publication: 2026 · Journal of clinical oncology
  • Top research focus: Lung Cancer Treatments and Mutations
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 37 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)13 trialsCarcinoma, Small Cell4 trialsSmall Cell Lung Carcinoma3 trialsBreast Cancer1 trialColorectal Cancer

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentCancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials1Industry payments17Publications1Libtayogeneric · CemiplimabClinical trials—Industry payments61Publications1Rybrevantgeneric · AmivantamabClinical trials1Industry payments17Publications—CisplatinClinical trials3Industry payments—Publications14Tecentriqgeneric · AtezolizumabClinical trials—Industry payments6Publications3DocetaxelClinical trials1Industry payments—Publications5Tagrissogeneric · OsimertinibClinical trials1Industry payments5Publications—Alimtageneric · PemetrexedClinical trials3Industry payments—Publications2EtoposideClinical trials2Industry payments—Publications3Abraxanegeneric · PaclitaxelClinical trials3Industry payments—Publications1CarboplatinClinical trials3Industry payments—Publications1GemcitabineClinical trials1Industry payments—Publications2

Works with

trial sponsors and companies reporting payments
Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments41Merck Sharp & Dohme LLCClinical trials—Industry payments24Janssen Biotech, Inc.Clinical trials—Industry payments18AstraZeneca Pharmaceuticals LPClinical trials—Industry payments17Pfizer Inc.Clinical trials—Industry payments14Seagen Inc.Clinical trials—Industry payments13AstraZeneca UK LimitedClinical trials—Industry payments11Genzyme CorporationClinical trials—Industry payments11Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments11Genentech USA, Inc.Clinical trials—Industry payments6Janssen Scientific Affairs, LLCClinical trials—Industry payments6SWOG Cancer Research NetworkClinical trials6Industry payments—University of California, DavisClinical trials6Industry payments—Gilead Sciences, Inc.Clinical trials—Industry payments5Sanofi-Aventis U.S. LLCClinical trials—Industry payments5Eisai Inc.Clinical trials—Industry payments4Amgen Inc.Clinical trials—Industry payments3Fosun Pharma USA Inc.Clinical trials—Industry payments3Jazz Pharmaceuticals Inc.Clinical trials—Industry payments3Merck Sharp & Dohme CorporationClinical trials—Industry payments3Abbvie Inc.Clinical trials—Industry payments2Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments2Coherus Biosciences Inc.Clinical trials—Industry payments2Daiichi Sankyo Inc.Clinical trials—Industry payments2Janssen Global Services, LLCClinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments2Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments1Boehringer Ingelheim International GmbHClinical trials—Industry payments1Boehringer Ingelheim S.A.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,114publications

Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.

55,117citations

Total citations across indexed works.

100h-index

Hirsch index (OpenAlex). i10-index 466.

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials ↓
37companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
7NIH grants · 1997–2025

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

All 15 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 66 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

Updated 14 Oct 2026

7 NIH research awards on record, funded 1997–2025 per NIH RePORTER. The latest:

All 49 award records: search, sort and filter.Explore →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 19 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    4,783 citations2016
    doi.org ↗
  2. 02
    Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
    3,221 citations2008
    doi.org ↗
  3. 03
    Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
    1,832 citations2005
    doi.org ↗
  4. 04
    Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    1,474 citations2009
    doi.org ↗
  5. 05
    Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
    1,429 citations2015
    doi.org ↗
All 1,114 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Philip C. Mack324Primo N. Lara287Karen Kelly225Mary W. Redman171Jonathan W. Riess139Roy S. Herbst107Fred R. Hirsch104Jieling Miao77Paul H. Gumerlock76James Moon74Angela M. Davies70William Holland67Derick Lau64Clifford G. Tepper62John J. Crowley60Shirish M. Gadgeel59James Keck55Kari Chansky54James H. Doroshow52Martin J. Edelman52Neal Goodwin52Susan Airhart51Mingshan Cheng51Carol J. Bult49Edison T. Liu48Regina Gandour‐Edwards48Paul Frankel47Suresh S. Ramalingam47John Crowley46Suzanne Miyamoto45Rebekah A. Tsai44Joel H. Graber44R. Krishna Murthy Karuturi43Xing Yi Woo43Joshy George43Konstantin H. Dragnev43Everett E. Vokes43Thomas H. Openshaw42Allen K. Simons42Jhanelle E. Gray42

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • X / Twitter

    x.com/drgandara

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • LinkedIn

    linkedin.com/in/david-gandara-md-361b55123

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Other

    health.ucdavis.edu/cancer/team/292/david-gandara---cancer---hematology-oncology---internal-medicine-sacramento

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
  • Other

    iaslc.org/iaslc-news/lung-cancer-considered/blood-based-testing-and-evolution-lung-cancer-dr-david-gandara

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
  • LinkedIn

    LinkedIn: "David Gandara, MD - Professor at UC Davis Comprehensive Cancer Center" (auth-walled; independently corroborated by two separate SERP passes matching institutional affiliation, title, and IASLC role)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certification: American Board of Internal Medicine

    Medical Oncology

    1979
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
  • Fellowship

    Hematology/Oncology, Letterman Army Medical Center, Presidio of San Francisco

    1978
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
  • Internship/Residency

    Internal Medicine, Madigan Army Medical Center, Tacoma, WA

    1976
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
  • Board Certification: American Board of Internal Medicine
    1976
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
  • M.D.

    University of Texas Medical Branch at Galveston

    1973
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
  • B.A.

    Zoology, University of Texas at Austin

    1969
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗

Editorial & leadership roles

journal and society appointments
  • Past President

    International Association for the Study of Lung Cancer (IASLC), 2009-2011

    2011
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
  • IASLC Treasurer (2017); World Conference on Lung Cancer President
    2009
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
  • Editor-in-Chief

    Clinical Lung Cancer journal; serves on editorial boards of multiple oncology journals

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • Principal Investigator

    NCI Early Therapeutics award / California Cancer Consortium; UCDCCC PI for Stand Up To Cancer KRAS-mutated lung cancer initiative

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.